Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
The KPV peptide is one of the smallest molecules routinely studied in inflammation research: a three-amino-acid sequence, lysine-proline-valine, that corresponds to the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). Because the pigment-driving portion of the parent hormone is absent from this fragment, investigators have used KPV to examine the anti-inflammatory arm of melanocortin biology largely apart from the receptor signaling that governs pigmentation.
This overview describes what the KPV peptide is, its molecular identity, and the two mechanistic routes most often reported for it in preclinical and in-vitro studies: melanocortin-receptor engagement and uptake through the intestinal peptide transporter PepT1. KPV is also the anti-inflammatory component that gives the KLOW research blend the letter K. Everything here reflects laboratory work in cell systems and animal models. These materials are supplied for research use only, not for human consumption.
What Is the KPV Peptide?
KPV carries the sequence Lys-Pro-Val, written KPV in single-letter code. It is the 11-13 fragment of alpha-MSH, meaning the final three residues of the thirteen-amino-acid parent hormone. Investigators became interested in this short fragment because the anti-inflammatory activity of alpha-MSH appeared to survive in its C-terminal tail, even after the melanocortin core responsible for pigmentation was removed. That observation, developed in foundational work by groups associated with Catania and Lipton, established KPV as a compact tool for studying inflammation signaling.
Structurally, the tripeptide is simple but not featureless. The proline at position two imposes a kink in the backbone that limits conformational flexibility and is thought to contribute to resistance against some peptidases. The N-terminal lysine carries a positive charge at physiological pH while the C-terminal valine provides a small hydrophobic end, producing a zwitterionic, modestly amphipathic molecule. At roughly 342 Da, its mass sits within the range handled by the di- and tripeptide carrier PepT1, a detail that becomes central to its intestinal research profile.
The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Reported Value |
|---|---|
| Sequence | Lys-Pro-Val (KPV) |
| Class | Tripeptide, C-terminal fragment of alpha-MSH (11-13) |
| Amino acid count | 3 residues |
| Molecular formula | C16H30N4O4 |
| Approximate molecular weight | ~342.4 g/mol |
| Solubility | Highly water soluble; lyophilized white powder |
| Studied focus | Anti-inflammatory signaling; NF-kB modulation |
Because the molecule is so small, suppliers typically confirm its identity by mass spectrometry optimized for low-mass species and report purity by HPLC. Researchers evaluating a batch can consult a guide to reading a peptide COA to interpret those figures against the values above.
Mechanism of Action in KPV Peptide Research
The mechanistic literature describes two non-exclusive routes by which KPV is studied, and individual experimental systems may engage one, the other, or both depending on which receptors and transporters the cells express.
Melanocortin-Receptor Signaling
The first route follows from the peptide’s origin as an alpha-MSH fragment. KPV has been reported to interact with melanocortin receptors, chiefly MC1R and to a lesser extent MC3R, on immune and epithelial cell populations such as monocytes, macrophages, and keratinocytes. Through this engagement, studies describe cyclic AMP and protein-kinase-A signaling that dampens the activation of NF-kB, a master transcription factor for pro-inflammatory gene programs.
PepT1-Mediated Uptake
The second, increasingly emphasized route involves the di- and tripeptide transporter PepT1 (SLC15A1). Work published in Gastroenterology by Dalmasso and colleagues reported that KPV is internalized by intestinal epithelial and immune cells through PepT1, and that this intracellular uptake is required for the peptide’s downregulation of NF-kB and MAP-kinase inflammatory signaling. PepT1 expression is normally low in the colon but rises under inflammatory conditions, which frames the transporter as a context-dependent gateway for the peptide’s activity. The two routes converge on the same downstream outcome: reduced transcription of NF-kB-responsive cytokines such as TNF-alpha, IL-1beta, and IL-6 in the systems studied.
Key Research Areas
Intestinal Inflammation Models
The most extensively cited body of KPV peptide research concerns preclinical models of intestinal inflammation. In murine colitis systems induced by dextran sulfate sodium (DSS) or trinitrobenzene sulfonic acid (TNBS), the tripeptide has been associated with reduced pro-inflammatory cytokine expression, preserved colonic architecture, and lower disease-activity scores relative to vehicle controls. The proposed basis is PepT1-mediated entry into both epithelial and lamina propria immune cells, linking the molecular mechanism to the tissue-level observations.
Dermatological and Keratinocyte Research
A second research thread examines KPV in skin-relevant models. Studies in cultured keratinocytes have reported attenuation of cytokine output following inflammatory challenge, consistent with NF-kB pathway modulation. This positions KPV alongside other skin-studied peptides, though its mechanism is distinct from that of the copper tripeptide GHK-Cu, which is investigated for matrix remodeling rather than melanocortin or PepT1 signaling.
NF-kB and Delivery-System Research
Across cell types, the convergence on NF-kB is one of the more consistent findings in the literature: reduced p65 nuclear translocation, less IkB degradation, and suppressed transcription of downstream cytokines. Because KPV is small, stable, and well characterized, it has also become a favored model cargo in nanoparticle and hydrogel delivery research, with 2025 and 2026 work continuing to use it in engineered oral-delivery and targeted-carrier studies aimed at inflamed intestinal tissue. This dual identity, a bioactive peptide of intrinsic interest and a workhorse test cargo, is unusual among short peptides.
KPV in the KLOW Blend and the Melanocortin Family
Within Rejuven8’s catalog, KPV is best known as the fourth component of the KLOW Blend. KLOW combines the three peptides of the GLOW base, GHK-Cu, BPC-157, and TB-500, and adds KPV to layer an anti-inflammatory signaling arm onto the matrix-remodeling, angiogenic, and actin-regulating pathways of the other three. The letter K in the KLOW acronym refers to this tripeptide.
Placing KPV against its melanocortin relatives clarifies what it offers as a research probe. The table below compares the tripeptide with its parent hormone and with GHK-Cu. These values reflect commonly reported laboratory attributes and are provided for comparison only.
| Peptide | Class | Length | Approx. weight | Studied focus |
|---|---|---|---|---|
| KPV | alpha-MSH (11-13) C-terminal fragment | 3 residues | ~342 Da | Anti-inflammatory, NF-kB modulation |
| alpha-MSH | Full melanocortin peptide | 13 residues | ~1665 Da | Pigmentation plus anti-inflammatory activity |
| GHK-Cu | Copper-binding tripeptide | 3 residues | ~340 Da (peptide) | Matrix remodeling, collagen signaling |
The comparison highlights KPV’s appeal as a selective tool: it retains the anti-inflammatory character of alpha-MSH while shedding most of the pigmentation activity, giving investigators a narrower probe of melanocortin-associated inflammation biology.
Research Considerations for Laboratory Use
KPV’s small size and high aqueous solubility simplify handling. Lyophilized material is generally kept frozen until reconstitution, after which its short backbone means it is used within a limited window and freeze-thaw cycling is minimized. Because the peptide is active in cytokine assays, low-endotoxin material and appropriate controls are advisable for any study with immune-cell readouts. General reconstitution chemistry is covered in the bacteriostatic water guide, and identity and purity documentation can be checked in the research peptide catalog. As a compact peptide with a defined mechanism, KPV is well suited to hypothesis-driven mechanistic work rather than to broad phenotypic screening.
Frequently Asked Questions
What is the KPV peptide?
KPV is a tripeptide of lysine, proline, and valine that corresponds to the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). It is investigated in preclinical research for anti-inflammatory signaling, particularly its modulation of the NF-kB pathway. It is a laboratory research compound only, supplied for research use, not for human consumption.
What is KPV peptide studied for?
In published preclinical and in-vitro work, KPV is studied for anti-inflammatory activity in intestinal, dermatological, and broader cytokine-challenge models. Its most cited literature concerns murine colitis systems, where it is associated with reduced pro-inflammatory cytokine expression and preserved tissue architecture.
How does KPV reduce inflammatory signaling?
Two mechanisms are reported. KPV can engage melanocortin receptors such as MC1R on immune and epithelial cells, and it can be taken up intracellularly through the PepT1 transporter. Both routes are associated with downregulation of NF-kB and MAP-kinase signaling and reduced transcription of pro-inflammatory cytokines in laboratory models.
What is the difference between KPV and alpha-MSH?
Alpha-MSH is the full thirteen-amino-acid parent hormone and engages the melanocortin receptors that drive pigmentation as well as anti-inflammatory pathways. KPV is only the final three residues, retaining much of the anti-inflammatory character while shedding most pigmentation activity, which makes it a more selective research probe.
How does KPV relate to the KLOW blend?
KPV is the fourth peptide in the KLOW blend and the source of the K in its name. KLOW adds KPV to the three-peptide GLOW base of GHK-Cu, BPC-157, and TB-500, contributing an anti-inflammatory signaling arm to the blend’s matrix, angiogenic, and actin research pathways.
Is KPV intended for human use?
No. KPV is a research compound offered for laboratory investigation only. It is not a medicine and is supplied for research use only, not for human consumption or self-administration.
References and Further Reading
- Foundational work characterizing alpha-MSH C-terminal tripeptides and anti-inflammatory activity (Catania, Lipton, and colleagues). PubMed: alpha-MSH KPV anti-inflammatory
- PepT1-mediated uptake of the tripeptide KPV and reduction of intestinal inflammation (Dalmasso and colleagues, Gastroenterology). PubMed: KPV PepT1 intestinal inflammation
- Melanocortin receptors as targets in the control of inflammation. PubMed: melanocortin receptor inflammation KPV
- KPV effects on NF-kB signaling in keratinocyte and epithelial models. PubMed: KPV keratinocyte NF-kB
- Nanoparticle and hydrogel delivery of KPV in colitis models. PubMed: KPV nanoparticle colitis delivery
- Colonic PepT1 (SLC15A1) expression in inflammatory bowel conditions. PubMed: PepT1 SLC15A1 colon inflammatory bowel
- Reviews of alpha-MSH-derived tripeptides in immune-mediated inflammation research. PubMed: alpha-MSH tripeptide review inflammation
